New meta-analysis below [1] [2].
Hard to believe that there are enough BAT studies to perform this particular meta-analysis (i.e. post-Abi/Enza).
Now we need to have studies of BAT (or LongBAT) to prevent CRPC.
"Bipolar androgen therapy (BAT) is a new endocrinologic treatment for castration-resistant prostate cancer (CRPC) that can restore some patients' sensitivity to drugs such as abiraterone (Abi) and enzalutamide (Enz). ...
"In a total of 108 unique records, ten studies were included in the final meta-analysis.
"Participants who underwent BAT achieved a PSA50 response rate of 27% ...
"Patients who completed BAT proceeded to AR-targeted therapy (Abi or Enz) and achieved a PSA50 response rate of 57% ...
"Patients with prior Enz resistance had a stronger impact on the PSA50 of AR-target therapy rechallenge.
"The results of this meta-analysis indicate that BAT is a safe and effective treatment for patients who have progressed after Abi or Enz. BAT can trigger the resensitization of patients with CRPC to subsequent endocrine therapy and improve the overall survival of patients and their quality of life." ...
-Patrick
[1] Full Text: readcube.com/articles/10.33...
[2] Abstract: pubmed.ncbi.nlm.nih.gov/371...